-

Quanterix to Participate in Contagion Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health, Kevin Hrusovsky will present at the Contagion Conference being held on Dec. 10, 2020. The conference will focus on COVID-19 testing and will mark the launch of The Virus Project, an initiative to address pandemics by fostering collaboration among the world’s leading scientists, physicians and entrepreneurs.

Hrusovsky will participate in the panel, “Understanding COVID-19 Testing,” at 1:30 p.m., EST, and deliver a presentation about Quanterix and Powering Precision Health at 2:10 p.m., EST.

To register for a day pass to the Contagion Conference, visit: https://www.thevirusproject.org/submit-stories-contact-us-2/.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

Media:
PAN Communications
Staci Didner, 407 734 7325
Pan.quanterix@pancomm.com

Investor Relations:
Stephen Hrusovsky
shrusovsky@quanterix.com

Quanterix Corporation

NASDAQ:QTRX

Release Versions

Contacts

Media:
PAN Communications
Staci Didner, 407 734 7325
Pan.quanterix@pancomm.com

Investor Relations:
Stephen Hrusovsky
shrusovsky@quanterix.com

More News From Quanterix Corporation

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD). This submission represents a significant milestone in the Company’s mission to provide superior, non-invasive, high-performance diagnost...

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individu...

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the “Inducement Grants”) were made to four employees in connection with the commencement of their employment. The Inducement Grants consist of 88,050 restricted stock units (“RSUs”) representing 88,050 shares of Quanterix common...
Back to Newsroom